Glaukos has patented a drug delivery ocular implant for targeted treatment of eye disorders. The device releases drugs in a controlled manner to reduce symptoms and manage intraocular pressure. The implant includes an outer shell, drug release element, and retainer for effective drug administration within the eye. GlobalData’s report on Glaukos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glaukos, Customized implants was a key innovation area identified from patents. Glaukos's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Ocular implant for controlled drug delivery
A drug delivery ocular implant has been granted a patent (Publication Number: US11992551B2) with a unique design aimed at controlled drug release within the eye. The implant consists of an outer shell defining an interior chamber, a drug release element with compression members and a membrane, and a retainer to secure the drug release element in place. The drug is released through a specific pathway within the drug release element, ensuring precise delivery from the proximal end of the outer shell.
The method of making the ocular implant involves assembling the components in a specific order, compressing the membrane to a predetermined state, and attaching a retainer to maintain the compression. The design allows for customization in terms of drug volume, elution rate, and overall size of the implant. The retainer, with bendable protrusions, plays a crucial role in retaining the compressed membrane within the outer shell. The implant also includes features like retention protrusions for anchoring at the target tissue site and an indentation on the exterior for ease of implantation and removal. Overall, the patent describes a sophisticated drug delivery system for ocular applications, offering controlled and precise drug release mechanisms within the eye.
To know more about GlobalData’s detailed insights on Glaukos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
